Form 4: Verastem Director Robert Gagnon Receives Equity Grant, Aligning Interests with Shareholders

Verastem, Inc. Director Robert E. Gagnon was granted 8,333 Restricted Stock Units and 12,500 stock options, aligning his compensation with the company's long-term performance.

Summary

• Robert E. Gagnon, a Director of Verastem, Inc. (VSTM), acquired 8,333 shares of common stock through Restricted Stock Units (RSUs) and 12,500 stock options on May 22, 2025.
• The RSUs were granted at a price of $0.00 per share and represent the contingent right to receive one share of common stock per RSU. Following this transaction, Mr. Gagnon beneficially owns 42,526 shares of common stock.
• The stock options have an exercise price of $7.48 per share and expire on May 22, 2035.
• Both the RSUs and stock options will vest in twelve equal monthly installments, starting from June 2025 through April 2026, with the final installment vesting on the earlier of the day before the 2026 Annual Meeting of Stockholders or May 31, 2026.
• Vesting for both equity grants is contingent upon Mr. Gagnon's continued service as a director of Verastem, Inc.

Sentiment

Score: 6

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests and is an expected part of director compensation, thus indicating a neutral to slightly positive sentiment without significant new operational news.

Positives

• The granting of equity (RSUs and stock options) to a director aligns their interests with those of shareholders, incentivizing long-term performance and value creation.
• The equity grants are part of the Issuer's Amended and Restated 2021 Equity Incentive Plan, indicating a structured and approved compensation framework.

Risks

• The vesting of both RSUs and stock options is conditional upon Robert E. Gagnon's continued service as a director of Verastem, Inc. If his service ceases, any unvested portions of the grants would be forfeited.

Future Outlook

The vesting schedule for the RSUs and stock options, extending through May 2026, implies an expectation of Robert E. Gagnon's continued service as a director for at least that period, ensuring ongoing alignment of his interests with the company's long-term goals.

Industry Context

Equity-based compensation, including Restricted Stock Units (RSUs) and stock options, is a common and widely accepted practice in the biotechnology and pharmaceutical industries. This approach is strategically utilized to attract, retain, and incentivize key personnel, such as directors and executives, by directly linking their financial interests to the long-term performance and success of the company.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a standard practice across publicly traded companies, including those in the biotech sector like Verastem, Inc.
• While specific grant sizes vary based on factors such as company size, financial performance, and individual roles, the structure of vesting over a defined period (e.g., 12 months) contingent on continued service is typical.
• Similar equity compensation structures are observed in comparable biotech companies, where executive and director compensation packages frequently include a significant equity component to foster long-term value creation and align interests with shareholders.

Corporate Governance

Related Party Transactions

• The acquisition of 8,333 Restricted Stock Units and 12,500 stock options by Robert E. Gagnon, a director of Verastem, Inc., constitutes a related party transaction as it involves compensation from the company to an insider.

Stakeholder Impact

• Shareholders: Potential for minor dilution from the future issuance of new shares upon RSU vesting and option exercise, but also benefits from increased alignment of director interests with long-term shareholder value creation.
• Employees: No direct impact on general employees is mentioned in this specific filing.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Next Steps

• Robert E. Gagnon's continued service as a director will be required to fulfill the vesting conditions for the granted RSUs and stock options.
• Potential exercise of stock options by Mr. Gagnon upon vesting and if market conditions are favorable.

Key Dates

Keywords

Verastem, VSTM, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Options, Director Compensation, Beneficial Ownership